Humira coverage guide: formulary, biosimilar landscape, prior authorization, and patient assistance

Humira (adalimumab, AbbVie) is a tumor necrosis factor (TNF) inhibitor and monoclonal antibody first approved by the FDA in 2002. It became the world's best-selling prescription drug, with nine FDA indications spanning rheumatology, dermatology, gastroenterology, and ophthalmology. But the access landscape has transformed: ten biosimilars are now FDA-approved, seven carry interchangeability designations, and all three major PBMs have excluded brand Humira from their 2026 national formularies in favor of preferred biosimilars.

This guide is for access teams, prior authorization coordinators, and prescribers navigating adalimumab coverage in a market defined by biosimilar competition and PBM-driven formulary exclusion.

Short answer

FDA-approved indications and dosing

Humira holds nine FDA-approved indications:

Rheumatoid arthritis (approved December 2002)

• Adults with moderately-to-severely active rheumatoid arthritis
• Dosing: 40 mg SC every other week; methotrexate or other non-biologic DMARDs commonly co-administered

Juvenile idiopathic arthritis (approved February 2008)

• Patients 2 years and older with moderately-to-severely active polyarticular JIA
• Dosing: weight-based (10 kg to <15 kg: 10 mg; 15 kg to <30 kg: 20 mg; 30 kg and above: 40 mg) every other week

Psoriatic arthritis (approved October 2005)

• Adults with active psoriatic arthritis
• Dosing: 40 mg SC every other week

Ankylosing spondylitis (approved July 2006)

• Adults with active ankylosing spondylitis
• Dosing: 40 mg SC every other week

Plaque psoriasis (approved January 2008)

• Adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy
• Dosing: 80 mg SC initial dose (week 0), then 40 mg SC at week 1, followed by 40 mg SC every other week starting at week 2

Crohn's disease (approved February 2007)

• Adults with moderately-to-severely active Crohn's disease
• Induction: 160 mg SC at day 1 (can be split as 4 injections in one day or 2 injections per day for 2 consecutive days), then 80 mg SC at day 15
• Maintenance: 40 mg SC every other week starting at day 29

Ulcerative colitis (approved September 2012)

• Adults with moderately-to-severely active ulcerative colitis
• Same induction and maintenance regimen as Crohn's disease

Hidradenitis suppurativa (approved September 2015)

• Adults with moderate hidradenitis suppurativa
• Dosing: 160 mg SC at day 1, 80 mg SC at day 15, then 40 mg SC every week starting at day 29

Uveitis (approved June 2016)

• Adults with non-infectious intermediate, posterior, and panuveitis
• Dosing: 80 mg SC at day 1, then 40 mg SC every other week starting at day 8

Biosimilar landscape

The adalimumab biosimilar market is the most crowded in the United States. As of May 2026, ten biosimilar products are FDA-approved:

Eight of the ten biosimilars carry interchangeability designations. Interchangeable biosimilars can be substituted at the pharmacy level without a new prescription, subject to state pharmacy practice law. The two non-interchangeable biosimilars (Yusimry, Idacio) require a new prescription if a payer mandates a switch from brand Humira.

High-list vs. low-list pricing strategy

The adalimumab biosimilar market has split into two pricing tiers:

• High-list-price biosimilars (Amjevita high-list, Cyltezo high, Hyrimoz high, Abrilada high, Hulio high, Idacio high, Yuflyma high): WAC near Humira's ~$6,923, competing on rebates to PBMs rather than point-of-sale price
• Low-list-price biosimilars (Hyrimoz low, Hadlima, Simlandi, Hulio low, Yusimry, Idacio low, Amjevita low-list, Abrilada low, Cyltezo low, Yuflyma low): WAC ranging from ~$899 to ~$2,769, offering 81-87% discount versus Humira WAC

The pricing tier matters for patient out-of-pocket cost. Patients with coinsurance or who are in the deductible phase generally pay less with low-list-price biosimilars.

PBM private-label biosimilar strategy

Each of the Big Three PBMs has created or partnered with a private-label biosimilar distribution entity:

These entities allow PBMs to capture more margin on biosimilar distribution and steer volume toward their preferred products.

Interchangeability and pharmacy substitution rules

Interchangeability determines whether a pharmacist can substitute a biosimilar for brand Humira without contacting the prescriber:

Key considerations:

• State law governs pharmacy substitution. Some states require prescriber notification after substitution; others require patient consent.
• Interchangeable biosimilars are not required to be substituted. A prescriber can indicate "dispense as written" or "brand medically necessary" to prevent substitution.
• Despite interchangeability, plans may still require prior authorization before covering any specific biosimilar product.
• Non-interchangeable biosimilars always require a new prescription if switching from brand Humira or from another biosimilar.

Payer coverage by major PBM (2026)

Express Scripts National Preferred Formulary

Brand Humira is excluded from the 2026 National Preferred Formulary. The only covered adalimumab products are preferred biosimilars:

Patients currently on brand Humira or non-preferred biosimilars must transition to a preferred product. Step therapy requires trial and failure of a preferred biosimilar before any non-preferred adalimumab product will be considered.

CVS Caremark

Brand Humira has been excluded since April 2024. Preferred biosimilars include Cordavis/Sandoz products and Biocon products. Key provisions:

• Most existing prior authorizations for Humira transfer automatically to the preferred biosimilar
• Step therapy applies for patients requesting brand Humira or non-preferred biosimilars
• Cordavis-labeled Hyrimoz is a primary preferred product

Optum Rx

Brand Humira is excluded from Premium and Select formularies. Preferred products:

Humira remains on tier 3 of the Select Standard formulary with prior authorization, but this is not the dominant formulary configuration.

Regional payer example: Point32Health (Harvard Pilgrim/Tufts)

Effective March 2026, Point32Health designated Simlandi as the preferred adalimumab product. Brand Humira and all other biosimilars are non-preferred or non-formulary. This exemplifies the trend of regional health plans aligning with biosimilar-only formularies.

Summary: 2026 PBM formulary positioning

The rebate dynamic

Despite the availability of low-list-price biosimilars offering 81-87% discounts versus Humira WAC, brand Humira historically held over 98% of adalimumab prescriptions at one point. This was driven by rebate dynamics: AbbVie offered rebates to PBMs that effectively made brand Humira cheaper for the PBM to process than lower-list-price biosimilars, even though patients paid more out of pocket. The 2026 formulary exclusions by all three major PBMs represent a structural shift away from this dynamic.

Medicare Part D coverage

Adalimumab products are covered under Medicare Part D. Key provisions for 2026:

Medicare Advantage and Part D plans may apply step therapy requiring a preferred biosimilar before brand Humira. The IRA's $2,100 cap applies regardless of which adalimumab product is dispensed.

Medicaid coverage

State Medicaid programs cover adalimumab products with prior authorization. Key features:

• Prior authorization required for all adalimumab products
• Many state Medicaid programs now require documented clinical justification for why a preferred biosimilar cannot be used before approving brand Humira
• Patient cost-sharing is typically minimal (varies by state, often $8/month or less)
• State Medicaid formularies may differ from commercial and Medicare formularies; verify with the specific state program

Prior authorization and step therapy

Prior authorization requirements

Prior authorization is required for all adalimumab products across all major commercial, Medicare, and Medicaid plans.

Typical PA criteria:

1. Confirmed diagnosis for one of the nine FDA-approved indications
2. Failure, contraindication, or intolerance to conventional therapies (e.g., methotrexate for RA; aminosalicylates, corticosteroids, immunomodulators for CD/UC)
3. Prescribed by or in consultation with an appropriate specialist
4. TB and hepatitis B screening completed
5. Not used in combination with other biologic DMARDs or targeted immunomodulators

Step therapy

Most major plans now require step therapy through a preferred biosimilar before brand Humira:

PA transfer for biosimilar switching

A critical access consideration: most major PBMs (CVS Caremark, Express Scripts, Optum Rx) transfer existing Humira prior authorizations to the preferred biosimilar automatically. This means patients switching from Humira to a preferred biosimilar do not need a new PA in most cases. However:

• If the preferred biosimilar has a different formulation (e.g., high-concentration vs. low-concentration), verify that the PA transfer covers the specific formulation
• Non-preferred biosimilars require a new PA regardless
• Medicaid PA transfer policies vary by state

Cost and pricing landscape

WAC price comparison

Low-list-price biosimilars offer 81-87% discounts versus Humira WAC. Actual net cost to payers depends on rebates, which are confidential and may differ substantially from WAC.

Cost by insurance type

For patients with coinsurance or high deductibles, low-list-price biosimilars result in meaningfully lower out-of-pocket costs compared with Humira or high-list-price biosimilars.

Patient assistance programs

Brand Humira (AbbVie)

Important: While Humira Complete provides copay support, brand Humira is effectively non-formulary on all major PBM national formularies in 2026. The savings program cannot override a formulary exclusion.

Biosimilar manufacturer programs

Each major biosimilar manufacturer offers its own patient support program:

Because preferred biosimilars are the only covered adalimumab products on most major formularies, these biosimilar manufacturer programs are now the primary pathway for patient copay assistance. Patients who were previously using Humira Complete should be transitioned to the support program for whichever biosimilar their plan prefers.

Independent low-cost options

The Mark Cuban Cost Plus Drug Company sells Starjemza (a Stelara biosimilar, not an adalimumab biosimilar) at $360 per dose. While this is not an adalimumab product, it demonstrates how low biosimilar prices can go when distributed outside traditional PBM rebate structures. Monitor for potential future adalimumab biosimilar offerings through similar channels.

What to monitor

• Additional payer formulary shifts: Regional health plans and Medicare Advantage plans continue to update formularies. Expect more plans to exclude brand Humira and designate preferred biosimilars during 2026-2027 formulary cycles.
• Biosimilar market share trajectory: Despite formulary exclusion, brand Humira's historical >98% prescription share shows that formulary position alone does not determine utilization. Track actual dispensing data as the market adjusts.
• Additional interchangeability designations: Yusimry and Idacio do not currently have interchangeability status. If they obtain it, pharmacy auto-substitution options expand.
• PBM private-label evolution: Monitor whether Quallent, Cordavis, and Nuvaila expand their biosimilar portfolios or change preferred products, which would affect which biosimilar patients receive.
• IRA expanded negotiation: Monitor whether adalimumab products are selected for future Medicare price negotiation rounds, which could affect Part D pricing and formulary dynamics.
• High-concentration formulation availability: Not all biosimilars are available in both high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations. Formulation mismatch can be a clinical barrier to switching for patients stabilized on a specific concentration.
• State Medicaid biosimilar mandates: Track state-level legislation mandating or incentivizing biosimilar use in Medicaid, which could accelerate adoption beyond commercial formulary changes.

Sources

• FDA biosimilar product information: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
• Express Scripts 2026 NPF: https://www.express-scripts.com/pdf/formulary/NPE1702_204612.pdf
• Drug Channels 2026 formulary exclusions: https://www.drugchannels.net/2026/01/the-big-three-pbms-2026-formulary.html
• PSLRx 2026 formulary review: https://phslrx.com/2026-formulary-exclusions-lists-a-review-of-express-scripts-cvs-caremark-and-optumrx/
• PMC, Formulary coverage of adalimumab products: https://pmc.ncbi.nlm.nih.gov/articles/PMC11157442/
• Cencora biosimilar landscape overview: https://www.cencora.com/resources/therapeutic-expertise/humira-biosimilar-landscape-overview
• CVS Specialty biosimilar resources: https://www.cvsspecialty.com/providers/choose-us/therapies/biosimilars.html
• Point32Health 2026 formulary update: https://www.point32health.org/provider/updates-humira-simlandi-and-stelara-012026
• The Rheumatologist biosimilar update: https://www.the-rheumatologist.org/article/biosimilar-update-2025-brings-more-fda-approvals-interchangeability/
• Drug Channels Humira biosimilar price war: https://www.drugchannels.net/2024/09/humira-biosimilar-price-war-update.html
• Biosimilars Council Humira landscape: https://biosimilarscouncil.org/resource/humira-biosimilar-landscape-still-waiting/